Stay updated on Tabelecleucel for EBV+ PTLD Clinical Trial
Sign up to get notified when there's something new on the Tabelecleucel for EBV+ PTLD Clinical Trial page.

Latest updates to the Tabelecleucel for EBV+ PTLD Clinical Trial page
- Check4 days agoChange DetectedThe study status was updated to Active, not recruiting on 2026-01-07. A new page revision (v3.3.4) was posted on 2026-01-07, replacing the previous v3.3.3 revision.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedExpanded recruitment sites across the US, Australia, and Europe and updated contact details; added new locations and investigators while removing some prior sites.SummaryDifference3%

- Check33 days agoChange DetectedUpdated the study record with December 2025 update timestamps and removed October 2025 timestamps, reflecting routine record maintenance rather than changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check54 days agoChange DetectedPublications section wording was updated to reflect that publications are automatically filled from PubMed, replacing the previous description, and the revision tag changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check62 days agoChange DetectedRemoved the government funding status notice banner, which previously informed users that information may not be up to date and NIH operations could be affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check76 days agoChange DetectedDeleted the previous ALLELE trial entry for EBV+ PTLD and added a new Phase 3 ALLELE entry with updated study procedures, an enrollment target of 115, expanded locations, and new contact details (Claire Fabre).SummaryDifference3%

Stay in the know with updates to Tabelecleucel for EBV+ PTLD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tabelecleucel for EBV+ PTLD Clinical Trial page.